Company intelligence / Profile preview

EQRx

Cambridge, Massachusetts, United Statesir.revmed.com ↗

Ownership: Public · EQRX
Development stage: Phase 3

Overview

EQRx launched with the mission to develop new, affordable medicines. Their lead programs included the EGFR inhibitor aumolertinib and the PD-L1 antibody sugemalimab. However, in 2022, the FDA rejected their approach of using interim data from China for approval of sugemalimab, which led to the company's eventual sale to Revolution Medicines in 2023[1].

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesantibodies
Industry: Biotech

Drug pipeline

3 assets

sugemalimab

Phase 3

Indications: Non-small cell lung cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Global Buyers Club

Financials

Market cap: $1.1B
Total revenue: $0
Enterprise value: $-69.7M

Beyond the preview

Go deeper on EQRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EQRx.

Explore the full profile